ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE and ECONOMIC PROBLEM

Overview

ECONOMIC PROBLEM is the #16 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 684 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to ECONOMIC PROBLEM. This represents approximately 1.6% of all 43,023 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience economic problem should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

ECONOMIC PROBLEM is a less commonly reported adverse event for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, but still significant enough to appear in the safety profile.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

In addition to economic problem, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

• BONE DENSITY DECREASED — 4,492 reports
• CHRONIC KIDNEY DISEASE — 2,605 reports
• BONE LOSS — 2,410 reports
• OSTEONECROSIS — 2,378 reports
• TOOTH LOSS — 2,247 reports
• MULTIPLE FRACTURES — 2,131 reports
• RENAL FAILURE — 2,086 reports
• OSTEOPOROSIS — 1,928 reports
• RENAL INJURY — 1,916 reports
• PAIN — 1,857 reports

Other Drugs Associated with ECONOMIC PROBLEM

The following drugs have also been linked to economic problem in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE cause ECONOMIC PROBLEM?

ECONOMIC PROBLEM has been reported as an adverse event in 684 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is ECONOMIC PROBLEM with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

ECONOMIC PROBLEM accounts for approximately 1.6% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.

What should I do if I experience ECONOMIC PROBLEM while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

If you experience economic problem while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages